Hormone KLOTHO Level in Heart Failure Patients That Participate in Rehabilitation Programme
30 patients suffering from Heart Failure with Ejection Fraction less than 40% start Cardiac Rehabilitation Programme, serum KLOTHO Hormone level and other labs and Echo measurements will be taken on the first visit.
After completion of 3-month Rehabilitation Programme the second set of labs and Echo measurements will be taken.
Than participants will be divided for 2 groups: the patients who wish to continue Rehabilitation programme for additional 3-month period and the second group that prefer to stop Rehabilitation programme after completion of the first 3 month period.
For both groups additional set of labs will be taken this time and at the end of the study.
The Aim of the study: to investigate association between serum KLOTHO level, physical activity and possible correlation with laboratory and echocardiographic parameters in cohort of Heart Failure patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
30 patients, age range older than 18 years old suffering from Heart Failure, Functional capacity II-III and echocardiographic evidence of Left Ventricular Ejection Fraction less than 40% beginning Cardiac Rehabilitation Programme. Following recruitment of patients to the study each one will undergo serum KLOTHO Hormone level assessment along with kidney functions, N terminal -Pro B-Type Natriuretic Peptide hormone activity and Echo measurements .
After completion of 3-months Exercise based Rehabilitation Programme set at 70-80% of maximal individual exercise capacity,a second identical set of lab tests and Echo measurements will be performed.
After than participants will be divided into 2 groups: Group I will comprise patients who wish to continue Rehabilitation programme for additional 3-months period and the Group II those who will stop Exercise Rehabilitation programme following completion of the first 3 months.
Both groups will undergo additional set of lab tests at this six-months-point. Except for the primary and secondary end-points all possible correlations between serum KLOTHO level and age, sex, Ejection Fraction, functional capacity, N terminal -Pro B-Type Natriuretic Peptide hormone activity hormone level and kidney function indices will be evaluated.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Eugeny Radzishevsky, MD
- Phone Number: 9724835394
- Email: eradzish@gmail.com
Study Contact Backup
- Name: Ehud Goldhammer, Prof
- Phone Number: 9724835394
- Email: ehud.goldhammer@b-zion.org.il
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Both genders
- Patients ≥ than 18 years
- Ejection Fraction ≤ than 40 %
Exclusion Criteria:
- Myocardial Infarction ≤ than 1.5 month before inclusion
- Renal failure with Creatinine ≥ 1.5 mg/dl
- Known Inflammatory condition.
- Patient taking Calcium Supplement,Vitamin D or pyrophosphate.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group I
15 patients who will continue participation in Exercise- Based Cardiac Rehabilitation Programme after completion initial 3-months period.
|
Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
Other Names:
|
|
Group II
15 patients who will stop participation in Exercise- Based Cardiac Rehabilitation Programme after the initial 3-months period.
|
Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum Klotho hormone level
Time Frame: "Baseline", "3 months" and "6 months"
|
Change in serum Klotho level between "Baseline", "3 months" and "6 months" visits
|
"Baseline", "3 months" and "6 months"
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Hospital Readmissions in patients with different serum level of KLOTHO
Time Frame: "3 months" and "6 months" and "1 Year"
|
"3 months" and "6 months" and "1 Year"
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Eugeny Radzishevsky, MD, Bnai Zion Medical Center- Ministry of Health, Israel
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 109-15-BNZ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
NCT07356843RecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)
-
NCT07199088RecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, Systolic
-
NCT02084992CompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart Failure
-
NCT03387813CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive
-
NCT03157219UnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart Failure
-
NCT07263035RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IV
-
NCT04281849CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure Acute
-
NCT01411735CompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
NCT07547540Not yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic
-
NCT00123955CompletedHeart Failure, Congestive | Diastolic Heart Failure
Clinical Trials on Exercise- Based Cardiac Rehabilitation Programme
-
NCT05326529CompletedCardiovascular Diseases
-
NCT00755131CompletedAcute Myocardial Infarction
-
NCT01432639Completed
-
NCT04790643CompletedCardiovascular Diseases | Cardiovascular Risk Factor
-
NCT04967235CompletedCardiovascular Diseases | Cardiac Risk Factors
-
NCT07468955CompletedCoronary Artery Disease | Coronary Heart Disease
-
NCT03907293CompletedMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Coronary Arteriosclerosis
-
NCT05498584RecruitingHeart Failure; With Decompensation
-
NCT04511182Not yet recruitingAcute Myocardial Infarction